Newsroom – Page 2 – Qnovia

Have a Project in Mind? Say Hi!

+1 800 123 456 789

+1 800 123 654 987

Mon - Sun: 10am - 10pm

27 Division St, New York,
NY 10002, USA

grido@mail.com

Newsroom

Press Releases

Media

December 13, 2022

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

November 16, 2022

Health Innovators – Brian Quigley and Mario Danek (Live from HLTH 2022)

November 2, 2022

The role of board members during a market downturn

November 2, 2022

The role of board members during a market downturn

October 19, 2022

Coruzant Technologies

Brian Quigley

October 7, 2022

Drug Delivery Business

How Qnovia aims to use inhaled therapeutics for smoking cessation

October 7, 2022

How Qnovia aims to use inhaled therapeutics for smoking cessation

October 4, 2022

Eyeing nicotine replacement market, Qnovia bags $17M to take inhaled delivery device into the clinic

October 4, 2022

Technology Networks

Qnovia, Inc. Raises $17 Million in Series A Funding To Advance Its Inhalable Therapeutics Pipeline

1
2
3
4

December 16, 2022

Qnovia Aiming For 2025 Approval Of Heatless Nicotine Nebulizer

December 13, 2022

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

November 16, 2022

Health Innovators – Brian Quigley and Mario Danek (Live from HLTH 2022)

November 8, 2022

Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

November 2, 2022

The role of board members during a market downturn

November 2, 2022

The role of board members during a market downturn

October 19, 2022

Brian Quigley

October 7, 2022

How Qnovia aims to use inhaled therapeutics for smoking cessation

October 7, 2022

How Qnovia aims to use inhaled therapeutics for smoking cessation

1
2
3
4